低中收入国家住院患者中抗生素耐药细菌所致血流感染的影响:系统综述与荟萃分析
该研究系统检索4个医学数据库,纳入109篇定量研究,荟萃分析低中收入国家成人住院患者中抗生素耐药细菌(ARB)血流感染(BSI)较抗生素敏感细菌(ASB)BSI的额外死亡率、住院时长、ICU入住和经济成本。结果显示ARB BSI患者粗死亡率OR 1.58、总住院时长SMD 0.49、ICU入住OR 1.96,人均额外直接医疗成本12,442美元,早死所致平均成本41,103美元。
要点
- 低中收入国家成人住院患者中,ARB BSI较ASB BSI粗死亡率升高(OR 1.58,95%CI 1.35–1.80,p<0.001)。
- ARB BSI患者总住院时长SMD 0.49、ICU入住OR 1.96,均较ASB BSI显著增加。
- ARB BSI人均额外直接医疗成本12,442美元,早死所致平均成本41,103美元。
核心结论
- 在资源有限地区,抗生素耐药与低中收入国家 substantial 的疾病和经济负担相关,但WHO区域、收入组和病原-药物组合间存在广泛异质性,且低中收入国家BSI数据匮乏。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、SCIELO、Scopus和WHO Global Index Medicus共4个医学数据库,初检n=13,012,最终纳入n=109篇定量研究。
- 仅纳入定量研究,排除高收入国家研究、无目标结局或血流感染来源不明确的研究。
- 粗死亡率、ICU入住和住院时长采用逆方差异质性模型进行荟萃分析,并按细菌革兰类型、科和耐药类型进行亚组分析。
- 经济成本中直接医疗成本每床日数据来源于WHO-CHOICE,死亡率成本基于早死所致潜在寿命损失的生产力损失估算,所有成本以2020年美元计。
- 采用MASTER框架评估研究质量和发表偏倚风险,仅对死亡率和ICU入住结局进行多变量荟萃回归。
主要发现
- 多数纳入研究显示ARB BSI较ASB BSI粗死亡率显著升高(OR 1.58,95%CI 1.35–1.80,p<0.001)。
- ARB BSI较ASB BSI总住院时长显著增加(SMD 0.49,95%CI 0.20–0.78,p<0.001)。
- ARB BSI较ASB BSI ICU入住显著增加(OR 1.96,95%CI 1.56–2.47,p<0.001)。
- 分析肠杆菌科、鲍曼不动杆菌和金黄色葡萄球菌的上中等收入国家非洲和西太平洋区域研究显示,每例患者ARB较ASB BSI的额外死亡率、住院时长和ICU入住最高。
- 多变量荟萃回归显示,耐药鲍曼不动杆菌BSI患者比较ARB与ASB BSI时死亡比值比更高(OR 1.67,95%CI 1.18–2.36,p 0.004)。
局限性
- 部分纳入研究质量较差,存在选择性抽样高风险或未能充分校正相关混杂因素。
- 结果显示WHO区域、收入组和病原-药物组合间存在广泛异质性。
- 低中收入国家BSI数据总体匮乏,妨碍国家层面政策实施和卫生进展追踪。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bloodstream infections (BSIs) produced by antibiotic-resistant bacteria (ARB) cause a substantial disease burden worldwide. However, most estimates come from high-income settings and thus are not globally representative. This study quantifies the excess mortality, length of hospital stay (LOS), intensive care unit (ICU) admission, and economic costs associated with ARB BSIs, compared to antibiotic-sensitive bacteria (ASB), among adult inpatients in low- and middle-income countries (LMICs). METHODS AND FINDINGS: We conducted a systematic review by searching 4 medical databases (PubMed, SCIELO, Scopus, and WHO's Global Index Medicus; initial search n = 13,012 from their inception to August 1, 2022). We only included quantitative studies. Our final sample consisted of n = 109 articles, excluding studies from high-income countries, without our outcomes of interest, or without a clear source of bloodstream infection. Crude mortality, ICU admission, and LOS were meta-analysed using the inverse variance heterogeneity model for the general and subgroup analyses including bacterial Gram type, family, and resistance type. For economic costs, direct medical costs per bed-day were sourced from WHO-CHOICE. Mortality costs were estimated based on productivity loss from years of potential life lost due to premature mortality. All costs were in 2020 USD. We assessed studies' quality and risk of publication bias using the MASTER framework. Multivariable meta-regressions were employed for the mortality and ICU admission outcomes only. Most included studies showed a significant increase in crude mortality (odds ratio (OR) 1.58, 95% CI [1.35 to 1.80], p < 0.001), total LOS (standardised mean difference "SMD" 0.49, 95% CI [0.20 to 0.78], p < 0.001), and ICU admission (OR 1.96, 95% CI [1.56 to 2.47], p < 0.001) for ARB versus ASB BSIs. Studies analysing Enterobacteriaceae, Acinetobacter baumanii, and Staphylococcus aureus in upper-middle-income countries from the African and Western Pacific regions showed the highest excess mortality, LOS, and ICU admission for ARB versus ASB BSIs per patient. Multivariable meta-regressions indicated that patients with resistant Acinetobacter baumanii BSIs had higher mortality odds when comparing ARB versus ASB BSI patients (OR 1.67, 95% CI [1.18 to 2.36], p 0.004). Excess direct medical costs were estimated at $12,442 (95% CI [$6,693 to $18,191]) for ARB versus ASB BSI per patient, with an average cost of $41,103 (95% CI [$30,931 to $51,274]) due to premature mortality. Limitations included the poor quality of some of the reviewed studies regarding the high risk of selective sampling or failure to adequately account for relevant confounders. CONCLUSIONS: We provide an overview of the impact ARB BSIs in limited resource settings derived from the existing literature. Drug resistance was associated with a substantial disease and economic burden in LMICs. Although, our results show wide heterogeneity between WHO regions, income groups, and pathogen-drug combinations. Overall, there is a paucity of BSI data from LMICs, which hinders implementation of country-specific policies and tracking of health progress.
引用
- Allel K, Stone J, Undurraga EA, et al. The impact of inpatient bloodstream infections caused by antibiotic-resistant bacteria in low- and middle-income countries: A systematic review and meta-analysis. PLoS Med. 2023. PMID: 37347726. doi:10.1371/journal.pmed.1004199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。